PSNL Personalis: Total Company Value-to-Revenue Ratio

Public company logo of Personalis (PSNL)

Personalis, Inc. (PSNL) minimizes risks by balancing retail diagnostics with support for pharma behemoths in genomic sequencing. The EV-to-sales ratio on GURU.Markets demonstrates the business value dynamics, where 17857.00 represents the latest metric reading. Personalis, Inc. (PSNL) is scaling its platform through test validation with global leaders, complementing this with joint research for precision cancer treatment.

personalis.com (PSNL): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

PSNL (Personalis Corp): analytical breakdowns and indicator data

- current price and projected stock value:
Fundamental company valuation:PSNL (personalis.com)
Mass-produced product of Personalis Inc

This indicator represents the ratio of total enterprise value to sales volume. The calculation combines market capitalization and net debt, allowing for an assessment of the asset's real price without the influence of debt load. Analyzing the EV-to-revenue ratio reveals whether the market has overvalued the company. For Personalis, Inc. (PSNL), this parameter reflects the investment value of scaling robotic systems and expanding genomic laboratory capacities.

Competitor analysis

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio